Ablynx successfully opposes Domantis' European patent appeal

22 January 2015

Belgian drug developer Ablynx (Euronext Brussels: ABLX) has successfully opposed the appeal lodged by Domantis over its European patent.

The latest decision by the Board of Appeal means that the patent will remain revoked in full, and that there is no further possibility for Domantis to appeal.

Domantis, now a member of the GlaxoSmithKline (LSE: GSK) group of companies, made the appeal against the decision by the Opposition Division of the European Patent Office to revoke the European Patent 1 517 921 in 2010.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK